Astb.Bo

ASTB.BO has a debt-to-equity ratio of 0.37, indicating a relatively conservative capital structure with a moderate reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 1.7, suggesting it can cover its short-term liabilities but with limited excess capacity. However, the company's operating cash flow is negative at -125,173,000 INR, which raises concerns about its ability to fund operations from core business activities. Free cash flow is positive at 33,734,000 INR, but this is significantly lower in magnitude than the operating cash flow deficit, indicating that capital expenditures are not fully offsetting operational cash outflows.

In terms of profitability, ASTB.BO reports a return on equity (ROE) of 24.8% and a return on assets (ROA) of 14.09%, both of which are strong indicators of efficient use of equity and assets to generate profit. These figures are well above the typical thresholds for the Pharmaceuticals industry, suggesting that the company is outperforming its peers in terms of capital efficiency and profitability.

The company's revenue is concentrated in a single business segment, as no segmental breakdown is provided in the available data. Geographically, the data does not specify revenue distribution by region, but the company's operations are likely centered in India given the INR financial reporting. This lack of geographic diversification may expose the company to regional economic or regulatory risks.

ASTB.BO's growth trajectory is not clearly defined in the available data, as no forward-looking revenue projections or historical growth rates are provided. The company's capital expenditures of 57,750,000 INR suggest ongoing investment in infrastructure or expansion, but the magnitude is relatively small compared to its total assets. Without additional context on the nature of these expenditures, it is difficult to assess their impact on future growth.

The company's risk profile includes a medium liquidity risk, primarily due to its negative net cash position after accounting for total debt. While dilution risk is assessed as low, the company's reliance on free cash flow to fund operations and capital expenditures may increase the likelihood of future equity or debt issuance if cash flow remains constrained. No specific dilution events are disclosed in the available data, but the company's financial structure suggests that it may need to raise additional capital in the near term.

No recent events, such as filings or transcripts, are provided in the available data to inform the company's current strategic direction or operational developments. The absence of such information limits the ability to assess the company's response to market conditions or regulatory changes.